Arabska Jaśmina, Margulska Aleksandra, Strzelecki Dominik, Wysokiński Adam
Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz , Lodz , Poland.
Department of Affective and Psychotic Disorders, Medical University of Lodz , Lodz , Poland.
Nord J Psychiatry. 2019 Nov;73(8):515-521. doi: 10.1080/08039488.2019.1658126. Epub 2019 Aug 29.
Brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) are involved in the processes of neurogenesis, synaptic plasticity, learning and memory. Growing number of studies shows a relationship between BDNF or MMP-9 and schizophrenia. Also, BDNF and MMP-9 levels may be affected by metabolic parameters, such as obesity or dyslipidemia. Our hypothesis is that alterations of BDNF or MMP-9 levels in schizophrenia might be secondary to metabolic abnormalities, often found among schizophrenia patients. We have compared BDNF and MMP-9 between patients with schizophrenia ( = 64, age 49 ± 8.2 y) and healthy controls ( = 32, age 51 ± 8.9 y) in the context of cardio-metabolic parameters. Serum levels of BDNF and MMP-9 were measured using ELISA test, body composition parameters were determined using bioelectric impedance analysis. Our results showed significantly lowered serum BDNF concentration in the schizophrenia group (schizophrenia: 23.8 ± 7.83 ng/mL, control: 27.69 ± 8.11 ng/mL, = 0.03). Serum MMP-9 concentration in schizophrenia group did not differ compared with the control group (schizophrenia: 456.8 ± 278.4 ng/mL, control: 341.5 ± 162.4 ng/mL, = 0.07). After adjusting for age, all anthropometric parameters, body composition and laboratory tests BDNF were still significantly lower in the schizophrenia group. However, MMP-9 became significantly elevated in the schizophrenia group after adjusting for several anthropometric and body composition covariates. Our results confirmed reduced serum BDNF concentration in patients with schizophrenia. Also, this reduction seems to be independent of metabolic abnormalities. On the other hand, our hypothesis that MMP-9 level in schizophrenia is altered due to metabolic abnormalities might be true.
脑源性神经营养因子（BDNF）和基质金属蛋白酶-9（MMP-9）参与神经发生、突触可塑性、学习和记忆过程。越来越多的研究表明BDNF或MMP-9与精神分裂症之间存在关联。此外，BDNF和MMP-9水平可能受代谢参数影响，如肥胖或血脂异常。我们的假设是，精神分裂症患者中BDNF或MMP-9水平的改变可能继发于代谢异常，而代谢异常在精神分裂症患者中很常见。我们在心脏代谢参数背景下比较了精神分裂症患者（n = 64，年龄49±8.2岁）和健康对照者（n = 32，年龄51±8.9岁）的BDNF和MMP-9水平。采用酶联免疫吸附测定（ELISA）检测血清BDNF和MMP-9水平，使用生物电阻抗分析确定身体成分参数。我们的结果显示，精神分裂症组血清BDNF浓度显著降低（精神分裂症组：23.8±7.83 ng/mL，对照组：27.69±8.11 ng/mL，P = 0.03）。精神分裂症组血清MMP-9浓度与对照组相比无差异（精神分裂症组：456.8±278.4 ng/mL，对照组：341.5±162.4 ng/mL，P = 0.07）。在调整年龄、所有人体测量参数、身体成分和实验室检查后，精神分裂症组的BDNF水平仍显著较低。然而，在调整了几个人体测量和身体成分协变量后，精神分裂症组的MMP-9水平显著升高。我们的结果证实了精神分裂症患者血清BDNF浓度降低。此外，这种降低似乎与代谢异常无关。另一方面，我们关于精神分裂症患者MMP-9水平因代谢异常而改变的假设可能是正确的。
